Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
Open Access
- 27 April 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 12 (4) , e1005535
Abstract
Monitoring the efficacy of novel reservoir-reducing treatments for HIV is challenging. The limited ability to sample and quantify latent infection means that supervised antiretroviral therapy (ART) interruption studies are generally required. Here we introduce a set of mathematical and statistical modeling tools to aid in the design and interpretation of ART-interruption trials. We show how the likely size of the remaining reservoir can be updated in real-time as patients continue off treatment, by combining the output of laboratory assays with insights from models of reservoir dynamics and rebound. We design an optimal schedule for viral load sampling during interruption, whereby the frequency of follow-up can be decreased as patients continue off ART without rebound. While this scheme can minimize costs when the chance of rebound between visits is low, we find that the reservoir will be almost completely reseeded before rebound is detected unless sampling occurs at least every two weeks and the most sensitive viral load assays are used. We use simulated data to predict the clinical trial size needed to estimate treatment effects in the face of highly variable patient outcomes and imperfect reservoir assays. Our findings suggest that large numbers of patients—between 40 and 150—will be necessary to reliably estimate the reservoir-reducing potential of a new therapy and to compare this across interventions. As an example, we apply these methods to the two “Boston patients”, recipients of allogeneic hematopoietic stem cell transplants who experienced large reductions in latent infection and underwent ART-interruption. We argue that the timing of viral rebound was not particularly surprising given the information available before treatment cessation. Additionally, we show how other clinical data can be used to estimate the relative contribution that remaining HIV+ cells in the recipient versus newly infected cells from the donor made to the residual reservoir that eventually caused rebound. Together, these tools will aid HIV researchers in the evaluating new potentially-curative strategies that target the latent reservoir. New therapies are being developed to permanently cure HIV infection. Many aim to reduce the pool of latent virus that persists despite years of treatment with antiretroviral drugs. Because latent virus is so difficult to sample and measure, often the only way to know if these new therapies have worked is to interrupt all treatment, and wait indefinitely to see if the infection rebounds. In this study we use a set of mathematical and statistical models to suggest optimal ways to design and interpret these treatment interruption trials. For various scenarios, we predict how long patients should be followed to be confident that they are cured, how frequent viral load sampling should occur, and how large clinical trials will need to be to estimate and compare drug efficacy. We demonstrate how to infer a range for number of remaining latent cells based on the timing of rebound after a long remission. As a case study, we apply these results to data from two HIV-positive patients who underwent bone marrow transplants and remained off treatment for months before suddenly rebounding. These findings can help inform the testing of new potentially-curative HIV therapies.Keywords
All Related Versions
Funding Information
- Foundation for the National Institutes of Health (DP5OD019851)
- National Institutes of Health (R01GM117591)
- National Institutes of Health (R01AI043222)
- National Institutes of Health (K23AI098480)
- National Institutes of Health (AI096113)
- National Institutes of Health (U19AI096109)
- amfAR, The Foundation for AIDS Research
- Johns Hopkins Center for AIDS Research (P30AI094189)
This publication has 57 references indexed in Scilit:
- Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruptionProceedings of the National Academy of Sciences, 2015
- Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trialThe Lancet HIV, 2014
- Stochastic variability in HIV affects viral eradicationProceedings of the National Academy of Sciences, 2014
- Loss and Recovery of Genetic Diversity in Adapting Populations of HIVPLOS Genetics, 2014
- A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral TherapyClinical Infectious Diseases, 2013
- Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin PatientPLOS Pathogens, 2013
- Developing strategies for HIV-1 eradicationTrends in Immunology, 2012
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferationNature Medicine, 2009
- Limits on Replenishment of the Resting CD4+ T Cell Reservoir for HIV in Patients on HAARTPLOS Pathogens, 2007
- Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cellsNature Medicine, 2003